Cantor Fitzgerald initiated coverage on Stratasys with a new price target
$SSYS
Computer peripheral equipment
Technology
Cantor Fitzgerald initiated coverage of Stratasys with a rating of Overweight and set a new price target of $24.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2024 | $24.00 | Overweight | Cantor Fitzgerald |
| 1/4/2023 | $15.00 | Hold → Buy | Needham |
| 11/8/2022 | Underperform → Mkt Perform | William Blair | |
| 8/17/2022 | $24.00 | Outperform | Credit Suisse |
| 5/17/2022 | $25.00 → $23.00 | Underweight → Neutral | JP Morgan |
| 2/24/2022 | $30.00 | Hold → Buy | Cross Research |
| 11/4/2021 | Neutral → Underweight | JP Morgan | |
| 11/4/2021 | Overweight → Neutral | JP Morgan |
Cantor Fitzgerald initiated coverage of Stratasys with a rating of Overweight and set a new price target of $24.00
Needham upgraded Stratasys from Hold to Buy and set a new price target of $15.00
William Blair upgraded Stratasys from Underperform to Mkt Perform
Schedules Fourth Quarter 2024 Conference Call for 8:30 a.m. ET on Wednesday, March 5, 2025 Stratasys Ltd. (NASDAQ:SSYS) ("Stratasys" or the "Company"), a leader in polymer 3D printing solutions, today announced unaudited preliminary approximate financial results for the fourth quarter 2024. Preliminary Fourth Quarter 2024 Results Revenue of $150.1 to $150.5 million, with hardware sequentially higher and consumables sequentially lower compared to the third quarter of 2024 GAAP gross margin of 46.0% to 46.5%, non-GAAP gross margin of 49.4% to 49.7%. GAAP operating loss of $13.3 to $14.4 million, non-GAAP operating income of $9.0 to $9.5 million GAAP net loss of $15.3 to $16.5
-Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -Innovative breast implant technology designed to address a $3.0 billion market opportunity -Cash and cash equivalents balance as of September 30, 2024 was $15.4 million -Conference call to be held today at 10:00 a.m. U.S. EDT – REHOVOT, Israel, Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration
Raises 2024 Margins and Profitability Outlook Revenue of $140.0 million, compared to $162.1 million in third quarter 2023 Eighth consecutive quarter of year-over-year growth in recurring consumables revenue reflects continued strong printer utilization Improved GAAP gross margin by 430bps to 44.8% and non-GAAP gross margin by 130bps to 49.6% compared to third quarter 2023 GAAP net loss of $26.6 million, or $0.37 per diluted share; non-GAAP net income resumes achieving profitability with $0.4 million, or $0.01 per diluted share $4.5 million of cash used in operations; year-to-date operating cash flow remains positive Adjusted EBITDA of $5.1 million Restructuring cost sa
Transaction at a Premium Underscores Leading Position in the Additive Manufacturing Industry and Positions Stratasys to Drive Growth Strengthens Balance Sheet to Capture Market Opportunities Fortissimo's Founding and Managing Partner, Yuval Cohen, to Join the Stratasys Board Stratasys Ltd. (NASDAQ:SSYS) ("Stratasys" or the "Company"), a leader in polymer 3D printing solutions, today announced that Fortissimo Capital ("Fortissimo"), a leading Israeli private equity fund investing in technology and industrials, has entered into an agreement to invest $120 million in the Company, acquiring approximately 14% of Stratasys' issued and outstanding ordinary shares through a direct purchase of
Stratasys highlights achievements in environmental, social, and governance initiatives, cementing its position as a supplier of choice for sustainable AM-enabled production solutions. Stratasys Ltd. (NASDAQ:SSYS) today announced the publication of its third Mindful Manufacturing™ ESG (Environment, Social, and Governance) and Sustainability Report. Prepared in accordance with the Global Reporting Initiative (GRI) and referencing SASB (Sustainability Accounting Standards Board) standards, the report underscores Stratasys' commitment to ESG excellence and enterprise risk management through best-in-class corporate governance, a people-first approach, meaningful social impact, and robust envir
Medical facilities and device manufacturers previously limited by constraints can now create patient-specific models to enhance surgical preparation, elevate patient outcomes, and fast-track innovation Stratasys Ltd. (NASDAQ:SSYS) today announced the launch of its J5™ Digital Anatomy™ 3D printer, the latest innovation designed to address the growing demand for cost-effective, high-fidelity anatomical models. This Stratasys innovation is designed to enable hospitals, medical device manufacturers and research institutions to enhance patient outcomes, streamline operations and bring products to market faster. This press release features multimedia. View the full release here: https://www.bu
6-K - STRATASYS LTD. (0001517396) (Filer)
6-K - STRATASYS LTD. (0001517396) (Filer)
8-A12B/A - STRATASYS LTD. (0001517396) (Filer)
SC 13G/A - STRATASYS LTD. (0001517396) (Subject)
SC 13G/A - STRATASYS LTD. (0001517396) (Subject)
SC 13G/A - STRATASYS LTD. (0001517396) (Subject)
The integration of Stratasys' J850 TechStyle™ solution empowers NYES to deliver innovative and sustainable fashion for global designers Stratasys (NASDAQ:SSYS) today announced that New York Embroidery Studio (NYES) has integrated the Stratasys J850 TechStyle™ printer into its manufacturing capabilities. Known for its innovation in design and production, NYES is leveraging this 3D Fashion® direct-to-textile printing technology to combine traditional embroidery with cutting-edge 3D printing, enabling new levels of creativity, personalization, and eco-conscious manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218604
Stratasys Direct's New ISO 13485 Certification Meets Stringent Regulatory Requirements Essential for Medical Device Manufacturers Stratasys Ltd. (NASDAQ:SSYS) today announced that its Stratasys Direct manufacturing facility in Tuscon, Arizona has achieved ISO 13485 certification, a globally recognized standard for quality management systems in medical device manufacturing. Stratasys plans to extend this certification to its other Stratasys Direct manufacturing facilities in Texas and Minnesota. By achieving ISO 13485 certification, Stratasys Direct is formally recognized for its safety, precision, and reliability of its 3D-printed components. This certification addresses critical regula
Schedules Fourth Quarter 2024 Conference Call for 8:30 a.m. ET on Wednesday, March 5, 2025 Stratasys Ltd. (NASDAQ:SSYS) ("Stratasys" or the "Company"), a leader in polymer 3D printing solutions, today announced unaudited preliminary approximate financial results for the fourth quarter 2024. Preliminary Fourth Quarter 2024 Results Revenue of $150.1 to $150.5 million, with hardware sequentially higher and consumables sequentially lower compared to the third quarter of 2024 GAAP gross margin of 46.0% to 46.5%, non-GAAP gross margin of 49.4% to 49.7%. GAAP operating loss of $13.3 to $14.4 million, non-GAAP operating income of $9.0 to $9.5 million GAAP net loss of $15.3 to $16.5